Inavolisib is a drug developed and produced by which pharmaceutical company

Inavolisib (R&D code: GDC-0077) is an innovative drug developed by Swiss pharmaceutical giant Roche (Roche). It is a third-generation highly selective PI3Kα inhibitor. The drug is mainly used to treat patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced or metastatic breast cancer that is resistant to endocrine therapy (ETR) and has PIK3CA mutations. In 2024October 10, inalise was approved for marketing by the FDA in the United States, becoming the first approved third-generation PI3Kα inhibitor.

Roche is a leading global biopharmaceutical company dedicated to the development and production of innovative medicines. The research and development of inarisep reflects Roche’s continuous investment and innovation capabilities in the field of tumor immunotherapy. The launch of this drug not only provides new treatment options for breast cancer patients, but also demonstrates Roche’s strategic layout in precision medicine.

In China, inariside was approved by the National Medical Products Administration (NMPA< span>) was approved for marketing in combination with palbociclib and fulvestrant for the treatment of endocrine therapy-resistant and PIK3CA mutated HR+/HER2- breast cancer patients. This marks the official entry of inariside into the Chinese market and provides patients with new treatment options.

In short, inalise is a third-generation highly selective PI3Kα inhibitor developed by Roche and is mainly used to treat specific types of breast cancer. Its global approval reflects Roche's continued innovation in the field of oncology treatment and its focus on patient needs.

Reference materials:https://www.drugs.com/